An Observational Post-Marketing Safety Registry of Sativex®
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this registry is to monitor safety outcomes of patients who are receiving
Sativex® for Multiple Sclerosis (MS) spasticity and for off-label indications in the United
Kingdom (UK), Germany and Sweden.